Brenzavvy
(Bexagliflozin)ApprovedSmall molecule
Brenzavvy is a small molecule that works as a SGLT2 Inhibitor.[2] It is being used across 4 indications, with its most advanced program in Approved.[1]
Brenzavvy is one of 113 small molecule programs targeting Essential Hypertension. It is currently in Approved.
4
Indications
16
Total Trials
1
Active Trials
112
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Brenzavvy
TTheracosbio
Approved
Byetta
AstraZenecaPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes4 trials
Interaction3 trials
Type 2 Diabetes Mellitus2 trials
Moderate Hepatic Impairment1 trial
4 more indications
Sleep Apnea1 trial
NEC1 trial
Essential Hypertension1 trial
Regulatory
FDA Approval Timeline[4]
Jan 20, 2023
BRENZAVVY
NDA NDA214373
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bexagliflozin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- SGLT2 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTheracosbio